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Background: The objective of this research was to examine treatment patterns and health-care costs associated
with second-step pharmacotherapy in patients with major depressive disorder (MDD) who initiated monotherapy
with a selective serotonin reuptake inhibitor (SSRI) in 2010.
Methods: This claims database study analyzed patients diagnosed with MDD who were prescribed a monotherapy
SSRI, with the first prescription identified as the index date. Patients were required to be ≥18 years old, to have
continuous insurance coverage from 1 year prior (pre-index) through 1 year post (post-index) from the index date,
and to have not received an antidepressant in the pre-index period. The analyses are descriptive of the patient
characteristics, initial SSRI prescribed, most commonly prescribed second-step therapies, and annualized health-care
costs.
Results: The identified patients (N = 5,012) were predominantly female (65.2%) with a mean age of 41.9 years. The
most frequent index SSRIs were citalopram (30.1%) and sertraline (27.5%), and 52.9% of patients were prescribed a
second-step pharmacotherapy during the post-index period. Add-on therapy occurred twice more frequently than
switching treatments, with either anxiolytics (40.2%) or antidepressants (37.1%) as the most common classes of
add-on pharmacological therapies. Patients who added a second medication or switched therapies had higher
annualized medical costs compared with patients who continued their index SSRI or discontinued treatment.
Conclusions: For patients who were initially treated with an SSRI therapy, approximately half were prescribed a
second-step treatment. In this comprehensive claims analysis, many of these patients experienced the addition of
second medication, rather than switching to a new therapy. Given the type of medications used, it is possible that
second-step interventions were targeted toward resolution of residual symptoms; however, this work is limited by
the use of claims data without information on dosing or clinical symptoms, side effects, or response. Findings from
this study set the expectation that physicians and patients will most likely need to partner for additional
interventions in order to achieve remission.
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For adults in the USA, the 12-month prevalence rate of
major depressive disorder (MDD) has been estimated at
8.3% with a lifetime prevalence rate of 19.2% [1]. Similar
rates across other countries indicate that MDD is a glo-
bal disease. Indeed, in the World Health Organization
(WHO) Global Burden of Disease 2010 study, mental and
substance use disorders were the fifth leading disorders of
global disability-adjusted life years, with MDD accounting
for 40.5% of this disability [2]. The burden of MDD is also
expressed through substantial direct and indirect costs. In
2000, the total economic burden of treating depression
in the USA was $83.1 billion. However, only 31% of these
costs include direct treatment ($26.1 billion); the majority
of the indirect costs involved workplace losses, with the
remainder involving costs attributed to suicide [3].
In this context, treatment of MDD becomes imperative.
Treatment guidelines recommend both pharmacotherapy
and psychotherapy for MDD [4]. From a pharmacological
perspective, selective serotonin reuptake inhibitors (SSRIs)
are recommended as the first-line pharmacological inter-
vention due to their favorable adverse event profile com-
pared with other antidepressants and generic availability
[4]. Ideally, with treatment, a patient would achieve remis-
sion of MDD, defined as being free or nearly free of symp-
toms. However, achievement of remission may be difficult
to obtain with monotherapy treatment. For example, in
the National Institute of Mental Health (NIMH)-funded
Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) study, approximately one third of patients achieved
remission during initial treatment with citalopram mono-
therapy, resulting in nearly two thirds of patients needing
additional treatment interventions [5].
When faced with inadequate or partial response to an
initial trial with an SSRI, physicians and patients often
discuss next whether to add another medication or
switch to a different therapy [6]. Although there is sup-
port for the efficacy of specific agents, the evidence to
guide choice of second-step treatment interventions for
individual patients, in general, is not clearly defined in
current treatment guidelines [7-9]. For patients who
have demonstrated a partial, positive response from an
initial therapy, it may be more beneficial to add to that
therapy, whereas for initial therapy associated with non-
response or significant adverse effects, switching is often
a recommended second step [7-9]. An important com-
ponent of this decision making should be consideration
of the patient’s preference about his or her treatment
[10]. In the STAR*D study, patients could select the
strategy, although not the specific agent, in the second
step of treatment. Patients had clear preference about
the acceptability of add-on therapy or switching, and few
were willing to accept both types of interventions. Pref-
erence for the type of second-step intervention was relatedto the initial efficacy response to the monotherapy as well
as the burden of adverse events associated with the treat-
ment [11].
Examining treatment patterns after initial monother-
apy with a SSRI can provide insight into the unmet med-
ical needs of patients with MDD as well as the current
state of second-step treatment practices. Accordingly,
the objective of this research was to examine treatment
patterns and outcomes of second-line pharmacotherapy
among patients with MDD who initiated monotherapy
with an SSRI. Patients were tracked for 1 year after they
initiated SSRI therapy, and information was obtained on
demographics, second-line pharmacological treatments,
and direct health-related costs.
Methods
Data for this study came from the Thomson Reuters
MarketScan® Commercial Claims and Encounters (CCAE)
Database from the USA. This claims database is fully
compliant with the United States Health Insurance and
Portability Act (HIPAA) privacy requirements while cap-
turing person-specific clinical utilization, expenditures,
and enrollment across inpatient, outpatient, prescription
drug, and behavioral services. The database includes large
employers, health plans, government organizations, and
public organizations, covering approximately 100 payers
and more than 500 million claims records. Paid claims
and encounter data are linked to detailed patient informa-
tion across sites and types of providers over time. Data
records examined for this study spanned the years 2009
through 2011.
For inclusion in this study, a patient was required to
be diagnosed with MDD in 2010–2011. Furthermore, to
ensure that patients were reliably diagnosed with MDD,
they needed to have at least one additional diagnosis claim
of MDD within 6 months following the initial diagnosis.
Patients were required to have a prescription for an SSRI
in 2010 (with the first prescription date identified as the
index date), to be at least 18 years old at the index date,
and to have continuous insurance coverage from 1 year
before the index date (the pre-index period) through 1 year
after the index date (the post-index period). Patients were
excluded from the analysis if they received a prescription
for any antidepressant in the pre-index period or if they
initiated therapy on more than one antidepressant.
For patients who met these study criteria, the treat-
ment pattern following the initial SSRI monotherapy
was then categorized as ‘continuation’, ‘switch’, ‘add-on’,
and ‘discontinuation’. Continuation was defined as the
use of SSRI therapy throughout the entire 1-year post-
index period. Switching was defined as the discontinu-
ation of SSRI treatment followed by the initiation of
therapy with another psychotropic agent. Add-on was
defined as adding another psychotropic agent during the
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was defined as patients who stopped SSRI therapy prior
to the end of the post-period without switching to any
other psychotropic medications.
Patient demographics, including age, sex, region of
residence, and type of insurance coverage, were analyzed
for the overall cohort. General health was approximated
using the Charlson comorbidity index [12], which mea-
sures 17 different categories of comorbidities and creates
a score that is a proxy of 10-year mortality rates. Add-
itionally, a chronic disease score was calculated as a
measure of aggregate comorbidity based on current con-
comitant medication use [13]. Descriptive statistics were
calculated for the type of initial SSRI therapy and the
second-step intervention. Direct health-care costs asso-
ciated with inpatient, outpatient, and medications were
also calculated for each pattern of treatment intervention.
For mean values, differences between the groups were ex-
amined using t statistics. When values were non-normally
distributed (for example, costs), Wilcoxon tests were used
to assess group differences. All analyses were conducted
using SAS, version 9.2, and findings of P values ≤0.05 were
considered statistically significant.Figure 1 Funnel plot for inclusion and exclusion criteria and sample sResults
In the database, 5,012 patients met the inclusion criteria.
For an attrition funnel diagram, refer to Figure 1. The
mean age of patients was 41.9 years (standard deviation
(SD) = 15.3 years), and approximately two thirds were fe-
male (65.2%). Patients were most commonly insured with
a preferred provider organization (54.3%) and resided in
the west (30.4%) or south (28.6%) regions of the USA. The
mean Charlson comorbidity index score was 0.5, and the
mean chronic disease score was 2.1 (see Table 1 for patient
characteristics). The most frequently prescribed SSRI as a
monotherapy was citalopram (30.1%), followed by sertra-
line (27.5%), escitalopram (18.7%), fluoxetine (17.9%), par-
oxetine (5.4%), and fluvoxamine (0.3%).
Of the initial 5,012 patients who started a monotherapy
SSRI, 30.7% (n = 1,545) of patients continued their therapy
with no change in the 1-year post-index period (Table 2).
These continuation patients had an average of 8.6 medi-
cation refills and a mean (SD) length of therapy of 9.3
(2.3) months. Add-on pharmacotherapy was prescribed
to 37.8% of the cohort. These add-on patients continued
their index SSRI, with an average of 7.8 refills and a mean
(SD) length of therapy of 7.7 (3.1) months for the indexize within the database.
Table 1 Demographics of patients with MDD who receive
initial treatment with SSRI monotherapy
Characteristic Initial treatment with




Age; mean (SD) 41.9 (15.3)












Non-capitated POS 449 (9.0)









Charlson comorbidity index; mean (SD), median 0.5 (1.1), 0.0
Chronic disease score; mean (SD), median 2.1 (2.5), 1.0
CDHP consumer-driven health insurance, COMP comprehensive medical
insurance, EPO exclusive provider organization, HMO health maintenance
organization, POS point of service, PPO preferred provider organization.












N = 1,510 N = 1,380 N = 936 N
n (%) n (%) n (%)
Continued 469 (31.1) 425 (30.8) 295 (31.5) 2
Discontinued 266 (17.6) 207 (15.0) 137 (14.6) 1
Switch 254 (16.8) 206 (14.9) 138 (14.7) 1
Add-on 521 (34.5) 542 (39.3) 366 (39.1) 3
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initial SSRI therapy to a different non-SSRI medication.
These switch patients only refilled their index SSRI an
average of 2.9 times, with a mean (SD) length of therapy
of 3.1 (2.7) months before changing therapy. Discontinu-
ation of the initial SSRI without further observed pharma-
cological intervention occurred for 16.0% of the cohort.
For these patients, the mean (SD) length of therapy was
3.6 (2.4) months, and they had 3.3 refills on average.
Among the patients who added a second class of medi-
cation to their SSRI therapy (n = 1,894, 38%), the most
commonly prescribed add-on medication classes were an-
xiolytics (40.2%) and antidepressants (37.1%), with the
most common being bupropion (15.4%) or tricyclics (pre-
dominantly trazodone hydrochloride) (15.8%). For patients
who switched from their SSRI therapy (n = 771, 15%), the
most commonly prescribed second-line classes were sero-
tonin norepinephrine reuptake inhibitors (SNRIs) (25.3%),
bupropion (24.1%), and benzodiazepines (17.9%) (Table 3).
Although there were some differences among the
absolute frequencies of second-step interventions as pro-
vided by different specialty physicians (Table 4), the order-
ing of the frequency of second-step interventions followed
a similar pattern across medical specialties. Within each
physician specialty, except for doctors of medicine (MDs)
(not elsewhere classified) and physicians in multispe-
cialty groups, add-on was the most frequent second step,
followed by continuation, discontinuation, and switching.
For unspecified MDs and physicians in multispecialty
groups, continuation was the preferred first option. Rates
of add-on therapy were highest in patients being seen by
physicians who were specialists in internal medicine and
obstetrics/gynecology (both 44%), and rates of switch were
highest in patients whose physicians were in family prac-
tice (19%) or in multispecialty physician practices (17%).
Overall, the cohort experienced very few MDD-related
inpatient hospitalizations or emergency room (ER) visits.
Across the entire cohort, 331 patients (6.6%) were hos-
pitalized for MDD-related diagnoses, while 63 (1.3%)
had MDD-related visits to an ER. Among the patients







= 899 N = 272 N = 15 N = 5,012
n (%) n (%) n (%) n (%)
86 (31.8) 66 (24.3) 4 (26.7) 1,545 (30.8)
45 (16.1) 43 (15.9) 4 (26.7) 802 (16.0)
20 (13.3) 48 (17.6) 5 (33.3) 771 (15.4)
48 (38.7) 115 (42.3) 2 (13.3) 1,894 (37.8)
Table 3 Frequency of different medication classes within





(N = 771) (N = 1,894)
n (%) n (%)
Antidepressants
SNRI 195 (25.3) 76 (4.0)
Bupropion 186 (24.1) 292 (15.4)
Tricyclic antidepressants 53 (6.9) 299 (15.8)
Other antidepressantsa 27 (3.5) 35 (1.8)
Total (antidepressants) 461 (59.8) 702 (37.1)
Anxiolytics
Benzodiazepine 138 (17.9) 727 (38.4)
Buspirone 10 (1.3) 34 (1.8)
Total (anxiolytics) 148 (19.2) 761 (40.2)
Anticonvulsants 47 (6.1) 106 (5.6)
Lithium 4 (0.5) 6 (0.3)
Second-generation antipsychotics
Quetiapine 15 (1.9) 43 (2.3)
Aripiprazole 9 (1.2) 65 (3.4)
Other second-generation
antipsychoticsb
2 (0.3) 45 (2.4)
Total (antipsychotics) 26 (3.4) 153 (8.1)
Stimulants 10 (1.3) 35 (1.8)
Norepinephrine reuptake inhibitor 3 (0.4) 10 (0.5)
Two-drug combination
Anxiolytic + antidepressant 33 (4.2) 42 (2.2)
Second-generation AP +
antidepressant
8 (1.0) 15 (0.8)
Two antidepressants 9 (1.2) 9 (0.5)
Second-generation AP + anxiolytic 0 (0) 15 (0.8)
Other 16 (2.1) 35 (1.9)
Total two-drug combinations 66 (8.6) 116 (6.12)
Combination of three or more drugs 6 (0.8) 5 (0.3)
AP antipsychotic. aOther antidepressants include nefazadone hydrochloride
and mirtazapine; bother second-generation antipsychotics include olanzapine,
risperidone, and ziprasidone.
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Patients who added pharmacotherapy experienced more
MDD-related outpatient visits, with a mean number of
15.2 (SD = 14.9). Mean annualized visits for patients who
continued index therapy (mean = 11.6, SD = 12.01) or who
discontinued index therapy (mean = 12.5, SD = 11.3) were
slightly lower.
Table 5 presents the annualized health-care costs
among patients, by second-step treatment intervention.
In general, patients who added to or switched from their
initial SSRI therapy had higher annualized costs acrossboth MDD-related and non-MDD-related services com-
pared with patients who continued with or discontinued
from their initial SSRI monotherapy. There were few
statistical differences in annualized costs between patients
who continued versus those who discontinued therapy
during the year.
Discussion
Consistent with findings from clinical effectiveness trials,
this study suggests that approximately a third of patients
who are treated with an SSRI will continue with mono-
therapy, while the majority of patients will require a
second-step intervention. Adjunctive or add-on therapy
was favored as a second-step intervention as compared
with switching, and this pattern was observed across dif-
ferent medical specialties. The most common second-
step interventions observed in this claims-based analysis
were benzodiazepines and tricyclic antidepressants (most
commonly trazodone). One hypothesis is that the add-
on therapy is being used for management of residual
symptoms. Insomnia, fatigue, anxiety, and cognitive
symptoms are frequent residual symptoms associated
with MDD [14], and they can also be adverse events as-
sociated with SSRI therapy [15]. Benzodiazepines are
likely used for their anxiolytic effects, and trazodone
may be prescribed for sleep-related symptoms. Similarly,
a common use for bupropion is to augment antidepres-
sant effects, but it may also be used to manage
treatment-emergent sexual dysfunction [16]. Interest-
ingly, despite regulatory approval as add-on therapy for
patients with inadequate response to an antidepressant
during the time period studied, there was limited use of
the second-generation antipsychotics.
While this study was restricted to patients who initi-
ated therapy on SSRI medications only, Schulz and Joish
[17] conducted a US claims study examining second-
step interventions among 7,273 patients with MDD who
initiated any antidepressant therapy from 2002 to 2006.
In their sample, 40.3% experienced a switch following
their initial antidepressant, 1.5% had an add-on medica-
tion, and 58.2% maintained their initial antidepressant
monotherapy. Another similar study was conducted by
Milea et al. [18]. In this US claims analysis of 134,287
adults and children prescribed new antidepressant treat-
ment in 2004–2006, 23.2% experienced a change in their
treatment. The most frequent changes were switch to
another antidepressant (9.5%) and combination with an-
other antidepressant (9.1%). Augmentation with an anti-
psychotic, anticonvulsant, or lithium added an additional
4.2% of patients to the combination therapy group, total-
ing 13.3% receiving add-on therapy. In Europe, a retro-
spective cohort study of medical records from 2008 to
2009 was conducted in Spain [19]. One advantage of
this study was the availability of patient information
Table 4 Distribution of second-step treatments by physician specialty
Second-step
intervention
Psychiatry Family practice Internal medicine Multispecialty group OB/GYN MD Unknown Other
N = 1,403 N = 1,090 N = 504 N = 339 N = 165 N = 336 N = 769 N = 406
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Continued 487 (34.7) 306 (28.1) 137 (27.2) 117 (34.5) 37 (22.4) 119 (35.4) 215 (28.0) 127 (31.3)
Discontinued 210 (15.0) 186 (17.1) 73 (14.5) 44 (13.0) 29 (17.6) 60 (17.9) 139 (18.1) 61 (15.0)
Switch 176 (12.5) 209 (19.2) 72 (14.3) 59 (17.4) 27 (16.4) 44 (13.1) 116 (15.1) 68 (16.7)
Add-on 530 (37.7) 389 (35.7) 222 (44.0) 119 (35.1) 72 (43.6) 113 (33.6) 299 (38.9) 150 (36.9)
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patients, 43% of patients were classified as having an
inadequate response to their initial monotherapy anti-
depressant treatment and were treated with a switch
(43.2%), an additional AD (15.5%), a dose increase
(14.6%), or continuation (26.7%) [19].
The differences in the frequencies of second-step
treatment interventions between the current study and
the above studies may be related to the study period.
Each study examined claims from years prior to the
2007 FDA approval of the antipsychotic aripiprazole for
the indication of the treatment of patients with inad-
equate response to antidepressant monotherapy or prior
to the EU approval of adjunctive treatment for MDD.
The advent of the approval of aripiprazole along with a
subsequent approval of quetiapine as an add-on ther-
apy for MDD has garnered greater attention to both
the unmet medical needs of patients with MDD and
the therapeutic option of add-on treatments [20]. An-
other difference among studies is that these prior studies
only included medications classified as antidepressants as
potential switch or add agents, whereas the present study
captured a broader range of psychotropic drug classes
commonly used in the treatment of patients with MDD
and thus increased the coverage for add-on therapy.
Notably, approximately a third of patients in this ana-
lysis continued with their treatment with monotherapy,
and only 15% discontinued pharmacological treatment
altogether. The rate of continuation is consistent with ex-
pectations that approximately one third of patients mayTable 5 Mean (SD) annualized health-care costs (in dollars) fo
MDD-related Non-M
Inpatient Outpatient ER Total MDD In
Mean (SD) Me
Continued 165 (1,980) 1,163 (1,496) 5 (77) 1,333 (2,567) 1,1
Discontinued 490 (5,252) 1,207 (1,532) 16 (154) 1,714 (5,519) 1,4
Switch 635 (4,036) 1,594 (2,909) 17 (202) 2,246 (5,644) 2,40
Add-on 1,074 (6,873) 1,859 (4,171) 21 (324) 2,954 (8,390) 2,70
Wilcoxon P value A, B, C, D, E A, B, C, D, E C, E, F A, B, C, D, E, F B
A difference between switched and added cohort is statistically significant (P < 0.05
significant (P < 0.05), C difference between switched and continued cohort is statist
cohort is statistically significant (P < 0.05), E difference between added and continue
and continued cohort is statistically significant (P < 0.05).be expected to remit with monotherapy [5]. The rates of
continuation may be also related to the inclusion require-
ment that patients have at least two codes of MDD. In a
previous database study based on health records from
general practitioners, one of the stronger predictors of
duration of treatment following new antidepressant treat-
ment was whether or not a depressive illness was coded in
the record [21].
With regard to costs, as might be expected, patients
who required second-step interventions of either add-on
therapy or switching were associated with higher total
health-related costs, possibly due to a more difficult to
treat illness. Previous work has demonstrated that patients
who require a switch generally present with a more acute
depressive illness that may include more previous episodes
of depression, comorbid psychiatric disorders, and/or
concurrent prescriptions of anxiolytic or hypnotic medica-
tions [22]. Both US and international studies have demon-
strated that patients who have a partial or non-response,
and who require additional treatment, are more costly
compared with patients who achieve remission with an ini-
tial treatment intervention [23,24].
The findings presented here should be interpreted in
the context of the limitations of the study design. First,
this study was conducted using an administrative claims
database and included only patients with medical and pre-
scription benefit coverage. As a result, the results may not
generalize well to other clinical populations. Second, as
the medical claims database does not include patient as-
sessments, the use of diagnostic codes served as a proxyr patients by second-step interventions
DD-related Overall
patient Outpatient ER Total non-MDD
an (SD) Mean (SD)
29 (6,949) 3,790 (8,701) 158 (674) 5,077 (12,608) 7,916 (14,008)
41 (8,015) 4,735 (16,492) 250 (752) 6,426 (20,217) 9,263 (23,459)
1 (12,878) 5,103 (8,306) 313 (1,011) 7,817 (18,516) 12,189 (20,863)
1 (19,719) 6,235 (13,461) 365 (1,494) 9,301 (26,426) 14,514 (30,044)
, C, D, E B, C, D, E C, D, E, F B, C, D, E A, B, C, D, E
), B difference between switched and discontinued cohort is statistically
ically significant (P < 0.05), D difference between added and discontinued
d cohort is statistically significant (P < 0.05), F difference between discontinued
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ments for identifying individuals with MDD. Third, with-
out measurement of patient response, the reasons behind
the selection of second-step interventions cannot be ascer-
tained. Fourth, this study did not examine the medication
dosage, which may also be a factor in treatment selection.
For example, quetiapine in low doses is used primarily to
ameliorate insomnia symptoms, whereas higher doses
are indicated for antidepressant efficacy. Recent publi-
cations have highlighted the great variability in dosing
of second-generation antipsychotics in the depressed
population and thus blurs these objectives [25,26]. Fi-
nally, while the indirect costs of MDD have been found
to be substantial [3], this analysis focused exclusively on
direct medical costs.
The strengths of this study include the overall size of the
sample and the real-world generalizability of data drawn
from a broad claims database. The findings reinforce the
medical needs of patients with MDD as prescription pat-
terns suggest that the majority of patients who are pre-
scribed an SSRI will need additional pharmacotherapy.
Further, the findings highlight the necessity for physicians
across different specialties to be aware that second-step
treatments are to be expected in the treatment of MDD.
With this perspective, physicians and patients can partner
together more confidently to individualize treatment to
achieve the goal of remission.
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